ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
A new company, Boston Pharmaceuticals, has been created by Gurnet Point Capital, the investment firm formed earlier this year by Swiss entrepreneur Ernesto Bertarelli and led by Christopher Viehbacher, former CEO of Sanofi. Gurnet says it is committing $600 million to Boston Pharma so the new firm can acquire clinical assets from academic, biotech, and pharmaceutical groups. The firm says it is agnostic to therapeutic area, focusing instead on validated mechanisms of action. It will be led by Viehbacher and Robert Armstrong, former head of external R&D at Eli Lilly & Co.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter